Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
about
Evasion and Immuno-Endocrine Regulation in Parasite Infection: Two Sides of the Same Coin in Chagas Disease?Translational challenges of animal models in Chagas disease drug development: a reviewErgosterol isolated from the basidiomycete Pleurotus salmoneostramineus affects Trypanosoma cruzi plasma membrane and mitochondria.Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitorsHost and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathyNitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.Chagas disease research and development: Is there light at the end of the tunnel?Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytesNovel drug discovery for Chagas disease.Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruziAssessing anti-T. cruzi candidates in vitro for sterile cidality.Putting Infection Dynamics at the Heart of Chagas Disease.Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.Biological factors that impinge on Chagas disease drug development.Adipose Tissue: A Safe Haven for Parasites?Reply to "Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs".Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole.4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease.HIV Persistence in Adipose Tissue Reservoirs.Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping.A novel nanoluciferase-based system to monitor Trypanosoma cruzi infection in mice by bioluminescence imaging.Experimental Chagas disease-induced perturbations of the fecal microbiome and metabolome.Bugging out over Chagas: Bioluminescent protozoans and old drugs might help unravel kissing-bug disease.Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasisStructural isomerism of Ru(ii)-carbonyl complexes: synthesis, characterization and their antitrypanosomal activitiesChallenges and recent progress in drug discovery for tropical diseases
P2860
Q26744672-EECD467C-50C6-4C7D-9A77-953C678CF420Q26796451-D277D6FE-D08F-4BE6-9148-D13741A5E051Q33743694-6600809D-9171-4A2B-BA79-336A14DB856EQ36286306-699D363D-BA94-4E22-A0BC-BB34623F61D4Q37272449-E8631A95-9BC2-42A7-8E16-9E9926866038Q37342932-1AF848C9-20A3-4D0F-A2B6-51EF699F0468Q37541623-6A10CBB3-557F-4EA3-AF1E-344387725BF0Q37714138-4A9F0FF9-4A7E-4B60-8D1C-D6E72B3F9316Q38770142-44552E4B-695C-41F5-92B4-08F4112AB446Q38919697-2542EB64-1C21-4C6F-94D7-2D1DABDF0340Q38929035-62DE01A0-1268-45CC-9C8C-0D461B98CF97Q38950397-A55B0325-0586-47F2-B355-AD72C9D889ADQ39003990-39B40D42-F835-4513-B49B-73946D7D141EQ39010376-915D411E-0D76-4524-A877-BDBE69C4C911Q39050802-2DFE3957-A0B0-431D-AEC6-EA1694D8B42FQ42625178-3E6B23E8-0BE0-490B-8FE8-FE18EEAEF314Q42625257-CDD6A576-C4F1-4B49-8B84-C14E23B4E82DQ47115930-CB05C14B-F83C-42BE-BD8A-5C29E720EDCFQ48342608-8A011B92-D9AA-48A2-8E3C-EB7C07D9771EQ50088418-BF9B11F5-A82B-4216-926F-B5BE846BE9D4Q50103799-EC409515-0C52-4814-B148-DE73102DE65CQ52334618-B9FFC7D8-88D5-4A3C-88E9-62C6746D18BDQ52577966-E86EFD69-7622-4BB4-B45F-9213C4D9A58DQ52660744-8DB67E03-E5C4-43CF-92EB-8297D45A8ED8Q52836242-5394AB31-E309-489C-A7C4-9AB299EF91F3Q57190987-9D996199-E5E1-493B-A5FC-3C2534AA8FB4Q58860526-274B19C0-2489-4ED4-A3A6-41DADB74E5DDQ59073293-FB762749-595F-444C-8561-83CCFE1D85FA
P2860
Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Limited Ability of Posaconazol ...... hly Sensitive In Vivo Imaging.
@ast
Limited Ability of Posaconazol ...... hly Sensitive In Vivo Imaging.
@en
type
label
Limited Ability of Posaconazol ...... hly Sensitive In Vivo Imaging.
@ast
Limited Ability of Posaconazol ...... hly Sensitive In Vivo Imaging.
@en
prefLabel
Limited Ability of Posaconazol ...... hly Sensitive In Vivo Imaging.
@ast
Limited Ability of Posaconazol ...... hly Sensitive In Vivo Imaging.
@en
P2093
P2860
P356
P1476
Limited Ability of Posaconazol ...... hly Sensitive In Vivo Imaging.
@en
P2093
Amanda Fortes Francisco
Eric Chatelain
John M Kelly
Shiromani Jayawardhana
P2860
P304
P356
10.1128/AAC.00520-15
P407
P577
2015-05-26T00:00:00Z